返回 A A A Font Size Receive E-mail Alerts Press Releases

MicroPort® Endovascular Listed as "2016 Shanghai Pudong New Area Enterprise R&D Institution"

[2017-04-21] 

Shanghai, China – Shanghai Pudong New Area Technology and Finance Committee recently released the list of Enterprise R&D Institutions in Pudong New Area, and MicroPort Endovascular (Shanghai) Co., Ltd. ("MicroPort® Endovascular") was listed among the 38 R&D institutions.
 
Since 2000, the district government of Pudong New Area started the verification work of Enterprise R&D institutions based on strict assessment standards in terms of the company's business condition, management mechanism, mid- and long-term R&D schedule, proportion of R&D staff, R&D input, as well as R&D intellectual property.
 
MicroPort® Endovascular primarily focuses on R&D, manufacturing, sales and technical support of the interventional medical devices in the treatment of aortic and peripheral vascular diseases. Product and Technology oriented, MicroPort® Endovascular is dedicated to the R&D and innovation of products with independent intellectual property. Up to date, MicroPort® Endovascular possesses and applied for 111 patents. Its Project of "Development and Industrialization of Key Technologies in Minimally Invasive Treatment of Aortic Diseases" won the First Prize of Shanghai Science and Technology Progress Award. Meanwhile, the company was listed as "2016 Shanghai Specialized, Sophisticated, Distinctive, Innovative SMEs," "2016 Shanghai Science and Technology Little Giant Enterprise (for Cultivation)," and "2015 Shanghai High- and New-Technology Enterprises."
 
Since MicroPort® Endovascular was listed as one of the Enterprise R&D Institutions in Pudong New Area, it signifies the recognition of government authority in MicroPort Endovascular's R&D abilities, company governance, mid- and long-term strategic goals, and development plans. The President of MicroPort® Endovascular Zhenghua Miao said: "MicroPort® Endovascular will continue to receive the developing concept of continuous innovation and enlarge our R&D input in the field of interventional treatment of aortic and peripheral vascular diseases, to provide patients with more high-quality medical devices with independent intellectual property rights."

About MicroPort®

MicroPort Scientific Corporation (the "Group") is a leading medical device company with business focusing on innovating, manufacturing, and marketing high-quality and high-end medical devices globally. With a diverse portfolio of products now being used at an average rate of one for every 15 seconds in thousands of major hospitals around the world, the Group maintains world-wide operations in a broad range of business segments including Cardiovascular, Orthopedic, Electrophysiological, Endovascular, Neurovascular, Surgical, Diabetes Care and Endocrinal Management, and others. MicroPort® is dedicated to becoming a patient oriented global enterprise improve and reshape patient lives through application of innovative science and technology.

For more information, please refer to: www.microport.com

Forward-Looking Statements

Some information contained on this website contains forward-looking statements. These forward-looking statements include, without limitation, those regarding our future financial position, our strategy, plans, objectives, goals and targets, future developments in the markets where we participate or are seeking to participate, and any statements preceded by, followed by or that include the words "believe", "intend", "expect", anticipate", "project", "estimate", "predict", "is confident", "has confidence" and similar expressions are also intended to identify forward-looking statements. Such statements are based upon the current beliefs and expectations of MicroPort®'s management and are subject to significant risks and uncertainties. MicroPort Scientific Corporation undertakes no obligation to update any of the statements. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and other factors that could cause actual future results to differ materially from current expectations include, but are not limited to, general industry and economic conditions, PRC governmental policies and regulations relating to the medical device manufacturing industry, competition in the medical device manufacturing industry, our ability to develop new products and stay abreast of market trends and technological advances, our goals and strategies, our ability to execute strategic acquisitions of, investments in or alliances with other companies and businesses, fluctuations in general economic and business conditions in China.

This document is for information purposes only and does not constitute or form part of any offer or invitation to sell or the solicitation of an offer or invitation to purchase or subscribe for any securities of MicroPort Scientific Corporation, and no part of it shall form the basis of, or be relied upon in connection with, any agreement, arrangement, contract, commitment or investment decision in relation thereto whatsoever.

All rights reserved.
Copyright © 2017 MicroPort Scientific Corporation

CONTACT:
Amanda Zhang
Corporate Culture & Public Relations Director
Shanghai MicroPort Medical (Group) Co., Ltd. (HQ)
Tel: (86)(21) 38954600-6989
Email: spokesperson@microport.com

 

[Prev]:MicroPort® Endovascular Attends 2017 Vascular Innovative Forum
[Next]:Two MicroPort® EP Products Counted in Ten Innovative Medical Devices Gaining CFDA Approval in 2016